Page 8 - ஜப்பானிய காப்புரிமை அலுவலகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Seelos Therapeutics Receives a Notice of Allowance in Japan for SLS-005 Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the Japanese Patent Office covering SLS-005 titled: “Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose”. The allowed claims … Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received a Notice of Allowance from the Japanese Patent Office (Japanese patent number 2016-512480) covering SLS-005 titled: “Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose”.

New yorkUnited statesAnthony marcianoJapanese patent officeSeelos therapeutics incParenteral administration of trehaloseHead of corporate communicationsSeelos therapeuticsProtein aggregation myopathicNeurodegenerative diseasesParenteral administrationTranscription factorCorporate communicationsபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்அந்தோணி மார்சியானோ